Impact of Idarucizumab and Andexanet Alfa on DOAC Plasma Concentration and ClotPro(®) Clotting Time: An Ex Vivo Spiking Study in A Cohort of Trauma Patients

Specific antagonists have been developed for the reversal of direct oral anticoagulants (DOAC). We investigated the impact of these reversal agents on the plasma concentration and visco-elastic test results of dabigatran and factor Xa inhibitors. After baseline measurements of dabigatran, the plasma...

Descripción completa

Detalles Bibliográficos
Autores principales: Oberladstätter, Daniel, Schlimp, Christoph J., Zipperle, Johannes, Osuchowski, Marcin F., Voelckel, Wolfgang, Grottke, Oliver, Schöchl, Herbert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396852/
https://www.ncbi.nlm.nih.gov/pubmed/34441771
http://dx.doi.org/10.3390/jcm10163476

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8396852/
https://www.ncbi.nlm.nih.gov/pubmed/34441771
http://dx.doi.org/10.3390/jcm10163476

Ejemplares similares